- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr John McMurray: Dapagliflozin Excels as a Preventive and Established Treatment for Heart Failure
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Dapagliflozin was shown to not only benefit patients at risk of heart failure, both with and without diabetes, but treat patients with established heart failure as well, said John McMurray, MD, FRCP, FESC, professor of medical cardiology in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow.
Transcript
Given the benefits that DAPA-HF revealed in preventing the worsening of heart failure in patients without diabetes, what is the potential role of dapagliflozin in primary prevention?
Dapagliflozin has 2 key roles when it comes to thinking about heart failure. The first is we have very strong evidence that dapagliflozin, and the whole SGLT2 inhibitor family, reduce the risk of incident heart failure. So, if you’ve got type 2 diabetes, 1 of the major risks you face is developing heart failure, and dapagliflozin, like other SGLT2 inhibitors, unequivocally reduces that risk substantially. What's new is that we now know that dapagliflozin is also a treatment for established heart failure. So, moving from prevention to treatment, we can treat patients with heart failure both with and without type 2 diabetes.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen
An Argument for Outpatient Bispecific Antibody Delivery: Dr Kirollos Hanna
January 25th 2025Bispecific antibodies have altered the multiple myeloma (MM) treatment landscape, but some practices still lack enough familiarity with these therapeutics to deliver them in outpatient settings.
Read More
